Dipyridamole increases gap junction coupling in bovine GM-7373 aortic endothelial cells by a cAMP-protein kinase A dependent pathway

J Bioenerg Biomembr. 2010 Feb;42(1):79-84. doi: 10.1007/s10863-009-9262-2. Epub 2010 Jan 7.

Abstract

The scrape-loading/dye transfer technique was applied on the bovine aortic endothelial cell line GM-7373 to analyze the effects of the antithrombolytic drug dipyridamole on gap junction coupling in endothelial cells. We found that a cell treatment for 24 h with dipyridamole in therapeutically relevant concentrations (1-100 microM) increased gap junction coupling in a dose dependent manner. Similar to dipyridamole, forskolin as well as 8-Br-cAMP increased the gap junction coupling, while dibutyryl-cGMP (db-cGMP) did not affect the gap junction coupling of the GM-7373 endothelial cells. In parallel, a pharmacological inhibition of protein kinase A (PKA) with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-89), antagonised the action of dipyridamole on gap junction coupling. We propose that the observed dipyridamole induced increase in gap junction coupling in endothelial cells is related to a cAMP-PKA dependent phosphorylation pathway. The report shows that gap junction coupling in endothelial cells is a suitable therapeutic target for treatment of cardiovascular diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cattle
  • Cell Line
  • Connexins / metabolism
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Dipyridamole / pharmacology*
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism*
  • Fibrinolytic Agents / pharmacology
  • Gap Junctions / drug effects*
  • Gap Junctions / metabolism*
  • Isoquinolines / pharmacology
  • Models, Biological
  • Protein Kinase Inhibitors / pharmacology
  • Sulfonamides / pharmacology

Substances

  • Connexins
  • Fibrinolytic Agents
  • Isoquinolines
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Dipyridamole
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide